0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Growth Hormone Secretion during Sleep

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The serum levels of insulin-like growth factor I (IGF I), dehydroepiandrosterone sulfate (DHAS), testosterone (T) and estradiol (E2) have been measured in 78 prepubertal and 57 early pubertal patients referred for short stature, at the same time when their secretion of GH was evaluated both during nocturnal sleep and by two conventional stimulation tests. According to the results of GH measurements they were considered as having a normal secretion of GH (group I), a complete GH deficiency (group II), a partial GH deficiency (group III), low responses to stimuli with normal secretion during sleep (group IV) or a nocturnal neurosecretory dysfunction (group V). Though widely scattered, the IGF I levels showed the following characteristics: a significant increase at puberty from 0.77 to 1.29 U/ml (p < 0.001) in the so-called endocrinologically normal patients of group I, not in the other groups; in the prepubertal patients of group I, a correlation of IGF I with chronological age (r = 0.47, p < 0.005) and bone age (r = 0.52, p < 0.002); significantly reduced IGF I levels in patients of group II having complete GH deficiency (p < 0.001); no significant differences between prepubertal patients with partial or atypical GH deficiency from groups III, IV, V and prepubertal patients from group I; lower pubertal levels in groups III, IV, V than in pubertal patients from group I (p < 0.01). The relationships of IGF I with steroids were weak but significantly positive with DHAS in the 78 prepubertal patients (r = 0.36, p < 0.001); positive with the logarithm of T in the early pubertal males (r = 0.31, p < 0.05); negative with the logarithm of E2 in the early pubertal females (r = 0.59, p < 0.06). No correlation with DHAS was found in pubertal patients. There were no correlations between the parameters of GH secretion and the plasma steroids. It may be suggested that before puberty IGF I is modulated in part by DHAS. At the early stages of puberty, in boys T but not DHAS increases the serum levels of IGF I, provided that GH secretion is normal. While in girls, serum E2 correlates negatively with the levels of IGF I. This correlation needs to be confirmed on a larger series of female adolescents.

          Related collections

          Author and article information

          Journal
          HRE
          10.1159/issn.0018-5051
          Hormone Research in Paediatrics
          S. Karger AG
          0018-5051
          2571-6603
          1990
          1990
          02 December 2008
          : 34
          : 1
          : 17-22
          Affiliations
          aClinique Médicale des Enfants, Hôpital Jean-Bernard-La-Milétrie, Poitiers, France; bFondation de Recherche en Hormonologie, Fresnes, France; c Hôpital Saint-Vincent-de-Paul, Paris, France
          Article
          181789 Horm Res 1990;34:17–22
          10.1159/000181789
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article